Ablative ultra-hypofractionated radiotherapy with surgical GI exclusion as a “functional spacer” for pancreatic cancer: a phase I safety and feasibility study
4 affiliations
- 1Department of radiation protection medicine, School of Preventive Medicine, Fourth Military Medical University, Xi’an, 710032 China
- 2Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Xi’an, 710032 China
- 3Department of Radiation Oncology, Air Force Medical Center, PLA, Beijing, 100142 China
- 4Department of Radiotherapy, Peking University Shougang Hospital, Beijing, 100144 China
Abstract
Objectives: The therapeutic window for radiotherapy in locally advanced pancreatic cancer (LAPC) is severely constrained by the anatomical proximity of the duodenum. We hypothesized that radiation-induced gastrointestinal (GI) injury is exacerbated by physiological digestion, and that surgically bypassing the irradiated duodenum would provide a biological “functional spacer.” We aimed to evaluate the safety and clinical feasibility of ablative ultra-hypofractionated radiotherapy (UHRT) followed directly by elective GI exclusion surgery.
Methods: In this prospective Phase I protocol, 10 patients with LAPC received ablative UHRT using Helical Tomotherapy at a prescribed dose of 40–60 Gy in 5 fractions. A prophylactic GI exclusion surgery (gastric truncation and GI bypass) was strictly scheduled within 7 days post-radiotherapy to place the high-dose irradiated duodenal segment into physiological quiescence. The primary endpoint was treatment safety assessed via CTCAE v4.02 and technical feasibility.
Results: All participants provided written informed consent and successfully completed the combined radiotherapeutic and surgical protocol. After a median follow-up of 12 months, no Grade 4–5 toxicities, bleeding, or gastrointestinal perforations were recorded. Only one patient (10%) experienced Grade 3 GI toxicity (abdominal pain). The Objective Response Rate (ORR) was 50%, with a 1-year overall survival rate of 60%. Furthermore, 70% of symptomatic patients achieved significant cancer-related pain relief.
Conclusions: Preliminary results suggest that the integration of ablative UHRT with an immediate prophylactic surgical GI bypass is a feasible and safe protocol. This “functional spacer” concept potentially mitigates the duodenal dose-limiting bottleneck, allowing the practical delivery of biologically ablative radiation doses in LAPC without catastrophic GI consequences. However, larger multi-center trials are warranted for further validation.
Trial registration: Not prospectively registered. At the time of study initiation in 2015, this investigator-initiated, single-center exploratory Phase I safety and technical feasibility study was reviewed and approved by the Institutional Ethics Committee of Air Force Medical Center, PLA, and public trial registration was not requested by the committee. The study was not designed as a randomized comparative efficacy trial, but rather as a pilot evaluation of the safety and feasibility of an individualized combined radiotherapy–surgical strategy. The protocol was approved by the Institutional Ethics Committee of Air Force Medical Center, PLA (Approval No. 2015-118-S01) on 12 March 2015.
Related
- Definitive Hypofractionated Radiotherapy in Elderly Patients With Non-melanoma Skin Cancer: Predicting Complete Response Using a Machine Learning-based Approach
- Radiotherapy Reprograms CCR8⁺ Regulatory T Cells via REL-NF-κB to Enforce Spatial Immune Exclusion in Hepatocellular Carcinoma.
- Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy
- Feasibility and potential benefits of daily online adaptive radiotherapy for head and neck cancer without margin reduction using an RTT-only workflow
- Impact of Histopathological Response on Outcomes After Surgical Resection Following Carbon‐Ion Radiotherapy for Pancreatic Cancer With Arterial Involvement
BibTeX
@article{di2026ablative,
title = {{Ablative ultra-hypofractionated radiotherapy with surgical GI exclusion as a “functional spacer” for pancreatic cancer: a phase I safety and feasibility study}},
author = {Yupeng Di and Tingyi Xia and Yingjie Wang and Gang Ren},
journal = {BMC Cancer},
year = {2026},
month = jun,
doi = {10.1186/s12885-026-16358-8},
url = {https://doi.org/10.1186/s12885-026-16358-8},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Ablative ultra-hypofractionated radiotherapy with surgical GI exclusion as a “functional spacer” for pancreatic cancer: a phase I safety and feasibility study
AU - Yupeng Di
AU - Tingyi Xia
AU - Yingjie Wang
AU - Gang Ren
PY - 2026
DA - 2026/06/17
JO - BMC Cancer
DO - 10.1186/s12885-026-16358-8
UR - https://doi.org/10.1186/s12885-026-16358-8
AB - Objectives: The therapeutic window for radiotherapy in locally advanced pancreatic cancer (LAPC) is severely constrained by the anatomical proximity of the duodenum. We hypothesized that radiation-induced gastrointestinal (GI) injury is exacerbated by physiological digestion, and that surgically bypassing the irradiated duodenum would provide a biological “functional spacer.” We aimed to evaluate the safety and clinical feasibility of ablative ultra-hypofractionated radiotherapy (UHRT) followed directly by elective GI exclusion surgery. Methods: In this prospective Phase I protocol, 10 patients with LAPC received ablative UHRT using Helical Tomotherapy at a prescribed dose of 40–60 Gy in 5 fractions. A prophylactic GI exclusion surgery (gastric truncation and GI bypass) was strictly scheduled within 7 days post-radiotherapy to place the high-dose irradiated duodenal segment into physiological quiescence. The primary endpoint was treatment safety assessed via CTCAE v4.02 and technical feasibility. Results: All participants provided written informed consent and successfully completed the combined radiotherapeutic and surgical protocol. After a median follow-up of 12 months, no Grade 4–5 toxicities, bleeding, or gastrointestinal perforations were recorded. Only one patient (10%) experienced Grade 3 GI toxicity (abdominal pain). The Objective Response Rate (ORR) was 50%, with a 1-year overall survival rate of 60%. Furthermore, 70% of symptomatic patients achieved significant cancer-related pain relief. Conclusions: Preliminary results suggest that the integration of ablative UHRT with an immediate prophylactic surgical GI bypass is a feasible and safe protocol. This “functional spacer” concept potentially mitigates the duodenal dose-limiting bottleneck, allowing the practical delivery of biologically ablative radiation doses in LAPC without catastrophic GI consequences. However, larger multi-center trials are warranted for further validation. Trial registration: Not prospectively registered. At the time of study initiation in 2015, this investigator-initiated, single-center exploratory Phase I safety and technical feasibility study was reviewed and approved by the Institutional Ethics Committee of Air Force Medical Center, PLA, and public trial registration was not requested by the committee. The study was not designed as a randomized comparative efficacy trial, but rather as a pilot evaluation of the safety and feasibility of an individualized combined radiotherapy–surgical strategy. The protocol was approved by the Institutional Ethics Committee of Air Force Medical Center, PLA (Approval No. 2015-118-S01) on 12 March 2015.
SN - 1471-2407
ER -